Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsResearchers showed that, dasatinib in melanoma stimulated its proper mechanism of resistance, independently of MAPK and PI3K/AKT pathway reactivation commonly associated to secondary c-Kit mutations, but through CRTC3/MITF/Bcl-2 pathway activation at clinically relevant doses.
[Molecular Cancer Research]
6606345 CHKUCJYE items 1 apa 0 default asc 1 160364 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-49783699eabf4e79d156eaf689482334%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CHKUCJYE%22%2C%22library%22%3A%7B%22id%22%3A6606345%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sabbah%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESabbah%2C%20M.%2C%20Krayem%2C%20M.%2C%20Najem%2C%20A.%2C%20Sales%2C%20F.%2C%20Miller%2C%20W.%2C%20Rincon%2C%20S.%20del%2C%20Awada%2C%20A.%2C%20Ghanem%2C%20G.%20E.%2C%20%26amp%3B%20Journe%2C%20F.%20%282021%29.%20Dasatinib%20stimulates%20its%20own%20mechanism%20of%20resistance%20by%20activating%20a%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20in%20melanoma%20with%20mutant%20or%20amplified%20c-Kit.%20%3Ci%3EMolecular%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-20-1040%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-20-1040%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6606345%26amp%3Bitem_key%3DCHKUCJYE%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dasatinib%20stimulates%20its%20own%20mechanism%20of%20resistance%20by%20activating%20a%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20in%20melanoma%20with%20mutant%20or%20amplified%20c-Kit%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malak%22%2C%22lastName%22%3A%22Sabbah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%22%2C%22lastName%22%3A%22Krayem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Najem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilson%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%20del%22%2C%22lastName%22%3A%22Rincon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Awada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghanem%20E.%22%2C%22lastName%22%3A%22Ghanem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Journe%22%7D%5D%2C%22abstractNote%22%3A%22Amplification%20or%20activating%20mutations%20of%20c-Kit%20are%20a%20frequent%20oncogenic%20alteration%20that%20occurs%20commonly%20in%20acral%20and%20mucosal%20melanoma.%20Among%20c-Kit%20inhibitors%2C%20dasatinib%20is%20the%20most%20active%20due%20to%20its%20ability%20to%20bind%20both%20active%20and%20inactive%20conformations%20of%20the%20receptor.%20However%2C%20its%20use%20as%20a%20single%20agent%20in%20melanoma%20showed%20limited%20clinical%20benefit.%20We%20first%20found%20that%20sensitivity%20to%20dasatinib%20is%20restricted%20to%20melanoma%20cell%20lines%20harbouring%20c-Kit%20alteration%20but%2C%20unexpectedly%2C%20we%20observed%20lower%20effect%20at%20higher%20concentrations%20that%20can%20readily%20be%20found%20in%20patient%20blood.%20We%20then%20investigated%20relevant%20pathway%20alterations%20and%20found%20complete%20inhibition%20of%20MAPK%20and%20PI3K%5C%2FAKT%20pathways%20but%20an%20increase%20in%20MITF%20and%20its%20downstream%20target%20Bcl-2%20through%20CRTC3%20pathway%20which%20turn%20on%20the%20CREB%20regulated%20transcription%20of%20MITF.%20More%20importantly%2C%20dasatinib%20up-regulates%20MITF%20and%20Bcl-2%20through%20SIK2%20inhibition%20revealed%20by%20CRTC3%20reduced%20phosphorylation%2C%20CREB%20transcription%20activation%20of%20MITF%2C%20MITF%20transcription%20activation%20of%20Bcl-2%20as%20well%20as%20pigmentation.%20Furthermore%2C%20overexpression%20of%20MITF%20renders%20melanoma%20cells%20resistant%20to%20all%20dasatinib%20concentrations.%20Selective%20Bcl-2%20inhibition%20by%20ABT-199%20or%20Bcl-2%20knock%20out%20restores%20the%20sensitivity%20of%20melanoma%20cells%20to%20dasatinib%2C%20validating%20the%20involvement%20of%20MITF%20and%20Bcl-2%20axis%20in%20the%20resistance%20of%20melanoma%20to%20dasatinib.%20In%20conclusion%2C%20we%20showed%20for%20the%20first%20time%20that%2C%20dasatinib%20in%20melanoma%20stimulate%20its%20proper%20mechanism%20of%20resistance%2C%20independently%20of%20MAPK%20and%20PI3K%5C%2FAKT%20pathway%20reactivation%20commonly%20associated%20to%20secondary%20c-Kit%20mutations%2C%20but%20through%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20activation%20at%20clinically%20relevant%20doses%20which%20may%20explain%20the%20weak%20clinical%20benefit%20of%20dasatinib%20in%20melanoma%20patients.%20Implications%3A%20Dasatinib%20stimulates%20its%20proper%20mechanism%20of%20resistance%20through%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20which%20may%20explain%20its%20modest%20clinical%20efficiency%20in%20melanoma%20patients%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1541-7786.MCR-20-1040%22%2C%22ISSN%22%3A%221541-7786%2C%201557-3125%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fmcr.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F03%5C%2F19%5C%2F1541-7786.MCR-20-1040%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-03-22T22%3A12%3A44Z%22%7D%7D%5D%7D
Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W., Rincon, S. del, Awada, A., Ghanem, G. E., & Journe, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.MCR-20-1040 Cite
